{"id":10564,"date":"2026-09-12T13:05:52","date_gmt":"2026-09-12T10:05:52","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=10564"},"modified":"2026-09-12T13:05:52","modified_gmt":"2026-09-12T10:05:52","slug":"esc-2026-statins-reduce-cardiovascular-events-in-healthy-adults-%e2%89%a570-even-without-high-ldl","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/esc-2026-statins-reduce-cardiovascular-events-in-healthy-adults-%e2%89%a570-even-without-high-ldl\/","title":{"rendered":"ESC 2026: Statins Reduce Cardiovascular Events in Healthy Adults \u226570 \u2014 Even Without High LDL"},"content":{"rendered":"<p><span>ESC 2026:<\/span><br \/>\n<span>Statins Reduce Cardiovascular Events in Healthy Adults \u226570 \u2014 Even Without High LDL<\/span><\/p>\n<p><span>STAREE Trial, August 29, 2026; simultaneously published in the New England Journal of Medicine.<\/span><\/p>\n<p><span>* Study: 9,971 \u201chealthy\u201dadults \u226570 years with no prior cardiovascular disease, randomized to atorvastatin 40 mg\/day vs placebo; median follow-up 5.9 years.<\/span><br \/>\n<span>* Baseline lipids: Mean LDL-C ~126 mg\/dL; importantly, high cholesterol was not required for enrollment.<\/span><br \/>\n<span>* MACE: 6.0% vs 8.3% \u2014 about 30% lower with atorvastatin.<\/span><br \/>\n<span>* Safety: Serious adverse events were similar overall; musculoskeletal events were modestly more frequent with atorvastatin.<\/span><br \/>\n<span>* Key message: Atorvastatin 40 mg reduced major cardiovascular events by 30% in apparently healthy adults \u226570 years, despite a relatively modest average baseline LDL-C of 126 mg\/dL\u2014not a selected hyperlipidemic population<\/span><\/p>\n<p><a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2607314\" target=\"_blank\" data-saferedirecturl=\"https:\/\/www.google.com\/url?q=https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2607314&amp;source=gmail&amp;ust=1789284448601000&amp;usg=AOvVaw0idJvY0yfF_prwfIDpA1Qu\" rel=\"noopener\">https:\/\/www.nejm.org\/doi\/full\/<wbr \/>10.1056\/NEJMoa2607314<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>ESC 2026: Statins Reduce Cardiovascular Events in Healthy Adults \u226570 \u2014 Even Without High LDL STAREE Trial, August 29, 2026; simultaneously published in the New England Journal of Medicine. * Study: 9,971 \u201chealthy\u201dadults \u226570 years with no prior cardiovascular disease, randomized to atorvastatin 40 mg\/day vs placebo; median follow-up 5.9 years. * Baseline lipids: Mean [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-10564","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10564","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=10564"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10564\/revisions"}],"predecessor-version":[{"id":10565,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10564\/revisions\/10565"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=10564"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=10564"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=10564"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}